Predictors of cognitive impairment in newly diagnosed Parkinson’s disease with normal cognition at baseline: A 5-year cohort study

作者：Jing Chen, Danhua Zhao, Qi Wang, Junyi Chen, Chaobo Bai, Yuan Li, Xintong Guo, Baoyu Chen, Lin Zhang, Junliang Yuan · 发表于：Frontiers in Aging Neuroscience · 年份：2023 · DOI：10.3389/fnagi.2023.1142558 · 被引用次数：27 · 研究领域：Parkinson's Disease Mechanisms and Treatments、Neurological disorders and treatments、Autism Spectrum Disorder Research

Background and objective Cognitive impairment (CI) is a substantial contributor to the disability associated with Parkinson’s disease (PD). We aimed to assess the clinical features and explore the underlying biomarkers as predictors of CI in patients with newly diagnosed PD (NDPD; less than 2 years). Methods We evaluated the cognitive function status using the Montreal Cognitive Assessment (MoCA) and a battery of neuropsychological tests at baseline and subsequent annual follow-up for 5 years from the Parkinson’s Progression Markers Initiative (PPMI) database. We assessed the baseline clinical features, apolipoprotein ( APO ) E status, β-glucocerebrosidase ( GBA ) mutation status, cerebrospinal fluid findings, and dopamine transporter imaging results. Using a diagnosis of CI (combined mild cognitive impairment and dementia) developed during the 5-year follow-up as outcome measures, we assessed the predictive values of baseline clinical variables and biomarkers. We also constructed a predictive model for the diagnosis of CI using logistic regression analysis. Results A total of 409 patients with NDPD with 5-year follow-up were enrolled, 232 with normal cognitive function at baseline, and 94 patients developed CI during the 5-year follow-up. In multivariate analyses, age, current diagnosis of hypertension, baseline MoCA scores, Movement disorder society Unified PD Rating Scale part III (MDS-UPDRS III) scores, and APOE status were associated with the development of CI. Predictiv...